北大医药: 第十一届监事会第八次会议决议公告

Meeting Overview - The 8th meeting of the 11th Supervisory Board of the company was held on August 22, 2025, with all 5 supervisors present, including participation via communication methods [1][4] - The meeting was chaired by the Supervisory Board Chairman, and it complied with relevant regulations [1] Financial Summary - The company summarized its operational performance for the first half of 2025 and prepared the corresponding half-year report and summary [1] - The profit distribution plan for the first half of 2025 was approved, proposing a cash dividend of 0.30 yuan per 10 shares, totaling 17,879,622.75 yuan (including tax) [2] Capital Reduction and Liquidation - The company received a request from its associate, Beijing Peking University Medical Oncology Hospital Management Co., Ltd., to reduce its registered capital from 300 million yuan to 100 million yuan due to severe operational difficulties [2] - The company plans to cooperate with the associate's capital reduction and subsequent liquidation process to optimize its investment layout and mitigate operational risks [2] Governance Structure Adjustment - The company proposed to adjust its governance structure by abolishing the Supervisory Board, transferring its powers to the Audit Committee of the Board of Directors, and revising relevant rules and regulations [3] - This proposal requires approval from the shareholders' meeting [3]